comparemela.com

Latest Breaking News On - Gamaleya institute of epidemiology - Page 1 : comparemela.com

Plasma Therapy: An Alternative to Antibiotics? - Innovation Toronto

Cold plasma jets could be a safe, effective alternative to antibiotics to treat multi-drug resistant infections

Moscow
Moskva
Russia
Yurov
Rostovskaya-oblast
Germany
German
Russian
Gamaleya-institute-of-epidemiology
Gamaleya-institute

250 Million Sputnik Doses For India in 8-10 Months, Says Dr Reddy's Executive

250 Million Sputnik Doses For India in 8-10 Months, Says Dr Reddy s Executive News18 1 hour ago Marya Shakil © Provided by News18 250 Million Sputnik Doses For India in 8-10 Months, Says Dr Reddy s Executive India will receive a total of 250 million doses of Russia’s Sputnik V over the next 8-10 months and its production here is expected to begin from July, a top executive at Dr Reddy’s, the local partner for the vaccine against Covid-19, said on Friday. The vaccine by Russia’s Gamaleya Institute is priced at Rs 948; its retail price of Sputnik V will be Rs 995.40 a dose with 5% GST. “The price which has been announced is Rs 948 plus GST for the imported dosages. Once we have the India-manufactured product available, the pricing for the vaccine will be different. We do not have a figure currently. We are working out the best possible ways to minimise the number so that it is accessible to as many Indians as possible,” Deepak Sapra, CEO, API & Ser

South-africa
Hyderabad
Andhra-pradesh
India
United-kingdom
Russia
Russian
South-african
Bharat
Deepak-sapra
Serum-institute-covishield
Gamaleya-institute-of-epidemiology

250 Million Sputnik Doses For India in 8-10 Months, Efficacy Against Variants Being Tested: Dr Reddy's Executive

250 Million Sputnik Doses For India in 8-10 Months, Efficacy Against Variants Being Tested: Dr Reddy s Executive News18 2 hours ago Marya Shakil © Provided by News18 250 Million Sputnik Doses For India in 8-10 Months, Efficacy Against Variants Being Tested: Dr Reddy s Executive India will receive a total of 250 million doses of Russia’s Sputnik V over the next 8-10 months and its production here is expected to begin from July, a top executive at Dr Reddy’s, the local partner for the vaccine against Covid-19, said on Friday. The vaccine by Russia’s Gamaleya Institute is priced at Rs 948; its retail price of Sputnik V will be Rs 995.40 a dose with 5% GST. “The price which has been announced is Rs 948 plus GST for the imported dosages. Once we have the India-manufactured product available, the pricing for the vaccine will be different. We do not have a figure currently. We are working out the best possible ways to minimise the number so that it is acc

South-africa
Hyderabad
Andhra-pradesh
India
United-kingdom
Russia
Russian
South-african
Bharat
Deepak-sapra
Serum-institute-covishield
Gamaleya-institute-of-epidemiology

250 Million Sputnik Doses For India in 8-10 Months, Efficacy Against Variants Being Tested: Dr Reddy's Official

Dr Reddy's Laboratories on Friday soft-launched imported COVID-19 vaccine Sputnik V, with Sapra taking the first shot in Hyderabad.

South-africa
Hyderabad
Andhra-pradesh
India
United-kingdom
Russia
Russian
South-african
Bharat
Deepak-sapra
Serum-institute-covishield
Services-at-dr

India to Get 250 Million Sputnik V Doses in 8-10 Months, Efficacy Against Variants Being Tested: Dr Reddy's

250 Million Sputnik Doses For India in 8-10 Months, Says Dr Reddy s Executive Marya Shakil © Provided by News18 250 Million Sputnik Doses For India in 8-10 Months, Says Dr Reddy s Executive India will receive a total of 250 million doses of Russia’s Sputnik V over the next 8-10 months and its production here is expected to begin from July, a top executive at Dr Reddy’s, the local partner for the vaccine against Covid-19, said on Friday. The vaccine by Russia’s Gamaleya Institute is priced at Rs 948; its retail price of Sputnik V will be Rs 995.40 a dose with 5% GST. “The price which has been announced is Rs 948 plus GST for the imported dosages. Once we have the India-manufactured product available, the pricing for the vaccine will be different. We do not have a figure currently. We are working out the best possible ways to minimise the number so that it is accessible to as many Indians as possible,” Deepak Sapra, CEO, API & Services at Dr Reddy’s,

South-africa
Hyderabad
Andhra-pradesh
India
United-kingdom
Russia
Russian
South-african
Bharat
Deepak-sapra
Serum-institute-covishield
Services-at-dr

vimarsana © 2020. All Rights Reserved.